Sonja M. Kagerer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sonja M. Kagerer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Anton F. Gietl
Institute for Regenerative Medicine (IREM), University of Zurich, Schlieren, Switzerland
1 shared publicationChristoph Hock
Institute for Regenerative Medicine (IREM), University of Zurich, Schlieren, Switzerland
1 shared publicationJiri M. G. van Bergen
Institute for Regenerative Medicine (IREM), University of Zurich, Schlieren, Switzerland
1 shared publicationKlaas P. Pruessmann
Institute for Biomedical Engineering, University of Zürich and ETH Zürich, Zürich, Switzerland
1 shared publicationLaetitia Vionnet
Institute for Biomedical Engineering, University of Zürich and ETH Zürich, Zürich, Switzerland
1 shared publicationPaul G. Unschuld
Department of Psychiatry, University of Geneva (UniGE), Geneva, Switzerland
1 shared publication
Latest Publications
- Open Access
- 2 July 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1598859
Hippocampal iron patterns in aging and mild cognitive impairment
Introduction: The entorhinal cortex (EC)-hippocampus system is critical for memory and affected early in Alzheimer’s disease (AD). Cognitive dysfunction in AD is linked to neuropathological changes, including non-heme iron accumulation in vulnerable brain regions. This study characterized iron distribution in the EC-hippocampus system using ultra-high field (UHF) magnetic resonance imaging (MRI) at 7 Tesla (T) in aging and mild cognitive impairment (MCI), an AD at-risk state.Methods: 40 participants (mean age [SD] 69.2 [7.42] years; 12 mild cognitive impairment (MCI), 28 cognitively healthy controls (HC)) underwent UHF MRI at 7 T with turbo spin echo and quantitative susceptibility mapping (QSM). Gray matter segmentation was performed using FreeSurfer software. Intraclass correlation coefficients (ICCs) were calculated for hippocampal and EC measures.Results: ICCs for mean susceptibilities were 0.61 overall, 0.58 for HC, and 0.69 for MCI, with significant group differences between HC and MCI (Kolmogorov–Smirnov test, k = 0.625, p ≤ 0.05).Discussion: Our findings suggest a higher coherence of non-heme iron distribution in MCI. An increasingly uniform distribution of iron in MCI could reflect a clinical continuum ranging from healthy aging to pathologic brain change and cognitive disorder. This highlights the potential of non-heme iron as a biomarker for early AD co-pathology.
- 2 July 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1598859
Open AccessHippocampal iron patterns in aging and mild cognitive impairment
Introduction: The entorhinal cortex (EC)-hippocampus system is critical for memory and affected early in Alzheimer’s disease (AD). Cognitive dysfunction in AD is linked to neuropathological changes, including non-heme iron accumulation in vulnerable brain regions. This study characterized iron distribution in the EC-hippocampus system using ultra-high field (UHF) magnetic resonance imaging (MRI) at 7 Tesla (T) in aging and mild cognitive impairment (MCI), an AD at-risk state.Methods: 40 participants (mean age [SD] 69.2 [7.42] years; 12 mild cognitive impairment (MCI), 28 cognitively healthy controls (HC)) underwent UHF MRI at 7 T with turbo spin echo and quantitative susceptibility mapping (QSM). Gray matter segmentation was performed using FreeSurfer software. Intraclass correlation coefficients (ICCs) were calculated for hippocampal and EC measures.Results: ICCs for mean susceptibilities were 0.61 overall, 0.58 for HC, and 0.69 for MCI, with significant group differences between HC and MCI (Kolmogorov–Smirnov test, k = 0.625, p ≤ 0.05).Discussion: Our findings suggest a higher coherence of non-heme iron distribution in MCI. An increasingly uniform distribution of iron in MCI could reflect a clinical continuum ranging from healthy aging to pathologic brain change and cognitive disorder. This highlights the potential of non-heme iron as a biomarker for early AD co-pathology.